Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
Holding HUMA?
Track your performance easily
Earnings Data
Report Date
Mar 21, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.25Last Year’s EPS
-$0.24Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2024
|% Change Since: -11.79%
|Next Earnings Date:Mar 21, 2025
Earnings Call Sentiment|Neutral
The call highlighted significant clinical advancements and strategic progress, particularly in the areas of regulatory achievements and clinical trial results. However, the delay in FDA review and increased financial losses pose notable challenges.Company Guidance
During the Humacyte Q3 2024 earnings call, key guidance metrics were highlighted, including the submission of a New Technology Add-on Payment (NTAP) application to the Centers for Medicare and Medicaid Services, targeting a reimbursement of up to approximately 65% of the sales price for their ATEV product, with effectiveness starting October 1, 2025. Additionally, a successful registered direct stock offering raised approximately $30 million. Research and development expenses were reported at $22.9 million for the quarter, while general and administrative expenses were $7.3 million, marking an increase due to preparations for the anticipated commercial launch of ATEV. The call also revealed a net loss of $39.2 million for the quarter and cash reserves of $71.0 million as of September 30, 2024.Positive Clinical Trial Results
Positive top-line results and sub-group analyses from the V007 Phase 3 clinical trial in hemodialysis were presented, showing superior function and patency of the ATEV compared to the current standard of care. Particularly notable improvements were seen in women, obese patients, and diabetic patients.
Successful Fundraising
Humacyte completed a registered direct offering of approximately $30 million, strengthening its financial position to support ongoing and future projects.
Regulatory Progress
The U.S. Patent Office allowed a patent for the BioVascular Pancreas (BVP) product candidate, and the FDA granted RMAT designation for the ATEV in the PAD indication, facilitating faster development and review.
Global Engagement and Recognition
Positive long-term results from the humanitarian program in Ukraine showed high rates of patency with no infections, amputations, or deaths related to ATEV, presented at the Military Health System Research Symposium.
---
HUMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HUMA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 08, 2024 | $5.26 | $5.78 | +9.89% |
| Aug 13, 2024 | $6.62 | $6.65 | +0.45% |
| May 10, 2024 | $4.52 | $4.70 | +3.98% |
| Mar 22, 2024 | $3.60 | $3.31 | -8.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Humacyte (HUMA) report earnings?
Humacyte (HUMA) is schdueled to report earning on Mar 21, 2025, TBA Not Confirmed.
What is Humacyte (HUMA) earnings time?
Humacyte (HUMA) earnings time is at Mar 21, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HUMA EPS forecast?
HUMA EPS forecast for the fiscal quarter 2024 (Q4) is -$0.25.
---